Cytokine & Growth Factor Reviews
Volume 21, Issue 2 , Pages 91-98 , April 2010

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics

  • K.J. Harrington

      Affiliations

    • The Institute of Cancer Research, Chester Beatty Laboratories, Targeted Therapy Laboratory, 237 Fulham Road, London SW3 6JB, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 020 7153 5157; fax: +44 020 7808 2235.
    • ,
  • R.G. Vile

      Affiliations

    • Molecular Medicine Program, Mayo Clinic, Rochester, MN, USA
    • ,
  • A. Melcher

      Affiliations

    • Leeds Institute of Molecular Medicine, Leeds, UK
    • ,
  • J. Chester

      Affiliations

    • Leeds Institute of Molecular Medicine, Leeds, UK
    • ,
  • H.S. Pandha

      Affiliations

    • The University of Surrey, Guildford, UK

References 

  1. Harrington KJ, Epenetos AA. Recent developments in radioimmunotherapy. Clin Oncol (R Coll Radiol). 1994;6:391–398
  2. Kohler G, Milstein C. Continuous culture of fused cells secreting antibodies of predefined specificity. Nature. 1975;256:495–497
  3. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumours. Cancer Res. 1990;50(Suppl.):814s–819s
  4. Courtenay-Luck NS, Epenetos AA, Moore R, Larche M, Pectasides D, Dhokia B, et al. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res. 1986;46:6489–6493
  5. Forni L, Coutinho A, Köhler G, Jerne NK. IgM antibodies induce the production of antibodies of the same specificity. Proc Natl Acad Sci USA. 1980;77:1125–1128
  6. Ledermann JA, Begent RH, Bagshawe KD. Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits. Br J Cancer. 1988;58:562–566
  7. Ledermann JA, Begent RH, Massof C, Kelly AM, Adam T, Bagshawe KD. A phase-I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int J Cancer. 1991;47:659–664
  8. Prestwich RJ, Errington F, Diaz RM, Pandha H, Harrington KJ, Melcher AA, et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther. 2009;20:1119–1132
  9. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 1999;5:881–887
  10. Kambara H, Saeki Y, Chiocca EA. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res. 2005;65:11255–11258
  11. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther. 2008;16:1665–1673
  12. Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, et al. Cyclophosphamide facilitates anti-tumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res. 2008;14:259–269
  13. Argyriou AA, Kalofonos HP. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Mol Med. 2009;15:183–191
  14. Harrington K, Alvarez-Vallina L, Crittenden M, Gough M, Chong H, Diaz RM, et al. Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery?. Hum Gene Ther. 2002;13:1263–1280
  15. Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther. 2009;17:1667–1676
  16. Fisher KD, Seymour LW. HPMA copolymers for masking and retargeting of therapeutic viruses. Adv Drug Deliv Rev. 2010;62:240–245
  17. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol. 2005;23:5795–5804
  18. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther. 2010;18:251–263
  19. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  20. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–28
  21. Adams DJ, Ridinger DN, Spendlove RS, Barnett BB. Protamine precipitation of two reovirus particle types from polluted waters. Appl Environ Microbiol. 1982;44:589–596
  22. Ridinger DN, Spendlove RS, Barnett BB, George DB, Roth JC. Evaluation of cell lines and immunofluorescence and plaque assay procedures for quantifying reoviruses in sewage. Appl Environ Microbiol. 1982;43:740–746
  23. Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg. 1963;77:29–37
  24. Tai JH, Williams JV, Edwards KM, Wright PF, Crowe JE, Dermody TS. Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. J Infect Dis. 2005;191:1221–1224
  25. Rosen L, Hovis JF, Mastrota FM, Bell JA, Huebner RJ. Observations on a newly recognized virus (Abney) of the reovirus family. Am J Hyg. 1960;71:258–265
  26. van den Wollenberg DJ, van den Hengel SK, Dautzenberg IJ, Cramer SJ, Kranenburg O, Hoeben RC. A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting. Gene Ther. 2008;15:1567–1578
  27. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol. 1977;54:307–315
  28. Strong JE, Lee PW. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol. 1996;70:612–616
  29. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science. 1998;282:1332–1334
  30. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998;17:3351–3362
  31. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–4689
  32. Vorburger SA, Pataer A, Swisher SG, Hunt KK. Genetically targeted cancer therapy: tumor destruction by PKR activation. Am J Pharmacogenomics. 2004;4:189–198
  33. Meurs E, Chong K, Galabru J, Thomas NS, Kerr IM, Williams BR, et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell. 1990;62:379–390
  34. Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. Reovirus: viral therapy for cancer “as nature intended”. Clin Oncol (R Coll Radiol). 2008;20:548–554
  35. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010;70:875–882
  36. Morris DG, Forsyth PA, Paterson AH, et al. A phase I clinical trial evaluating intralesional reolysin (reovirus) in histologically confirmed malignancies. Proc Am Soc Clin Oncol. 2002;
  37. Forsyth P, Roldán G, George D, Wallace C, Palmer CA, Morris D, et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther. 2008;16:627–632
  38. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008;14:7127–7137
  39. White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, et al. Characterisation of the innate, humoral and cellular immune response to intravenous oncolytic reovirus (Dearing Type 3) during a phase I clinical trial. Gene Ther. 2008;15:911–920
  40. Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther. 2008;10:362–370
  41. Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther. 2008;10:371–379
  42. Zhang M, Li S, Li J, Ensminger WD, Lawrence TS. Ionizing radiation increases adenovirus uptake and improves transgene expression in intrahepatic colon cancer xenografts. Mol Ther. 2003;8:21–28
  43. Qian J, Yang J, Dragovic AF, Abu-Isa E, Lawrence TS, Zhang M. Ionizing radiation-induced adenovirus infection is mediated by Dynamin 2. Cancer Res. 2005;65:5493–5497
  44. Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res. 2008;14:912–923
  45. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55
  46. Vidal L, Twigger K, White CL, Ahmed M, Pandha HS, Nutting CM, et al. Phase I trial of intratumoral administration of reovirus type 3 (Reolysin) in combination with radiation in patients with advanced malignancies. Proc Am Assoc Cancer Res. 2005;
  47. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879–885
  48. Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res. 2009;15:6158–6166

PII: S1359-6101(10)00017-1

doi: 10.1016/j.cytogfr.2010.02.006

Cytokine & Growth Factor Reviews
Volume 21, Issue 2 , Pages 91-98 , April 2010

Article Tools

* Image Usage & Resolution